Habib Bennaceur: Novo Nordisk Completed its Acquisition of Zaltenibart from Omeros Corporation
Habib Bennaceur, SVP Rare Disease Unit at Novo Nordisk, shared on LinkedIn:
”I am pleased to share that Novo Nordisk completed its acquisition of zaltenibart from Omeros Corporation strengthening our commitment to address unmet needs in rare blood and kidney disorders.
This addition expands our portfolio in haematology and renal as we continue working to serve more people and communities living with rare diseases.
Zaltenibart is an investigational antibody designed to precisely target MASP-3 in the complement system, representing a novel mechanism of action for our haemato-renal portfolio.
Early clinical data in paroxysmal nocturnal haemoglobinuria (PNH) is encouraging, and we look forward to advancing zaltenibart’s development and exploring its potential to provide new treatment options as we drive lasting change in rare disease.”
Stay updated with Hemostasis Today.
-
Oct 25, 2026, 18:36James P. Crowley: Gene Inactivation and Targeted Gene Repair as Two Approaches to CRISPR Gene Editing
-
Oct 25, 2026, 17:43Jan Sloves: Femoral Vein Aneurysm and Chronic Venous Obstruction
-
Oct 25, 2026, 17:31Kasimu Hussaini: Blood Component Therapy From Whole Blood to Targeted Treatment
-
Oct 25, 2026, 17:23Zahra Safarzadeh: When Low Factor VII Activity and Reduced VWF Antigen Coexist
-
Oct 25, 2026, 17:17Anubhav Joshi: Evans Syndrome in CLL A Differential Diagnosis to Remember
-
Oct 25, 2026, 17:04Tehila Alter: Tracking Hematopoietic Cell Engraftment in Bone Marrow Using CEST MRI
-
Oct 25, 2026, 16:45Shauna RileyÖ‰ First Guidelines for Hemoglobin SC Disease
-
Oct 25, 2026, 16:26Heghine Khachatryan: Patient Safety and Clinical Judgment in Platelet Transfusion Decisions
-
Oct 25, 2026, 16:13Funmi (Vanessa) Ullam: From Lived Experience to Research and Innovation in Sickle Cell Care